A Study of LY2216684 in Participants With Impaired Hepatic Function
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of liver function on how much of the
study drug (LY2216684) gets into the blood stream and how long it takes the body to get rid
of it. Information about any side effects that may occur will also be collected.
The duration of participation in this study is approximately 12 days, not including the
screening visit. This study requires 1 clinic confinement of 5 days/4 nights followed by 1
out-patient follow-up visit. A screening visit is required within 30 days prior to the start
of the study. This research study will be an open-label study.
The study involves a single oral dose of 18 milligrams (mg) LY2216684 given as 2 tablets.